Zolpidem CR and Hospitalized Patients With Dementia

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
DementiaAlzheimer DiseaseDementia, VascularSleep DisordersCircadian Dysregulation
Interventions
DRUG

Zolpidem CR

After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.

DRUG

Placebo

After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.

Trial Locations (1)

02144

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Massachusetts General Hospital

OTHER